Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Navigation/Suche
- Forscher*innen
- Institutionen
- Projekte
- Publikationen
- Partner
- Geldgeber
- Ausstattung
- Knowhow
- Forschungsfelder
"Köpfe" der aktuellen Meldungen:
Gewählte Publikation:
SHR Neuro Krebs Kardio Lipid Stoffw Microb
Trieb, M; Rainer, F; Stadlbauer, V; Douschan, P; Horvath, A; Binder, L; Trakaki, A; Knuplez, E; Scharnagl, H; Stojakovic, T; Heinemann, Á; Mandorfer, M; Paternostro, R; Reiberger, T; Pitarch, C; Amorós, A; Gerbes, A; Caraceni, P; Alessandria, C; Moreau, R; Clària, J; Marsche, G; Stauber, RE.
HDL-related biomarkers are robust predictors of survival in patients with chronic liver failure.
J Hepatol. 2020; 73(1):113-120
Doi: 10.1016/j.jhep.2020.01.026
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
- Führende Autor*innen der Med Uni Graz
- Marsche Gunther
- Rainer Florian
- Stauber Rudolf
- Trieb Markus
- Co-Autor*innen der Med Uni Graz
- Binder Lukas
- Douschan Philipp
- Gruden Eva
- Heinemann Akos
- Horvath Angela
- Scharnagl Hubert
- Stadlbauer-Köllner Vanessa
- Stojakovic Tatjana
- Trakaki Athina
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- BACKGROUND & AIMS: High-density lipoprotein cholesterol (HDL-C) levels are reduced in patients with chronic liver disease and inversely correlate with disease severity. During acute conditions such as sepsis, HDL-C levels decrease rapidly and HDL particles undergo profound changes in their composition and function. We aimed to determine whether indices of HDL quantity and quality associate with progression and survival in patients with advanced liver disease. METHODS: HDL-related biomarkers were studied in 508 patients with compensated or decompensated cirrhosis (including acute-on-chronic liver failure [ACLF]) and 40 age- and gender-matched controls. Specifically, we studied levels of HDL-C, its subclasses HDL2-C and HDL3-C, and apolipoprotein A1 (apoA-I), as well as HDL cholesterol efflux capacity as a metric of HDL functionality. RESULTS: Baseline levels of HDL-C and apoA-I were significantly lower in patients with stable cirrhosis compared to controls and were further decreased in patients with acute decompensation (AD) and ACLF. In stable cirrhosis (n = 228), both HDL-C and apoA-I predicted the development of liver-related complications independently of model for end-stage liver disease (MELD) score. In patients with AD, with or without ACLF (n = 280), both HDL-C and apoA-I were MELD-independent predictors of 90-day mortality. On ROC analysis, both HDL-C and apoA-I had high diagnostic accuracy for 90-day mortality in patients with AD (AUROCs of 0.79 and 0.80, respectively, similar to that of MELD 0.81). On Kaplan-Meier analysis, HDL-C <17 mg/dl and apoA-I <50 mg/dl indicated poor short-term survival. The prognostic accuracy of HDL-C was validated in a large external validation cohort of 985 patients with portal hypertension due to advanced chronic liver disease (AUROCs HDL-C: 0.81 vs. MELD: 0.77). CONCLUSION: HDL-related biomarkers are robust predictors of disease progression and survival in chronic liver failure. LAY SUMMARY: People who suffer from cirrhosis (scarring of the liver) have low levels of cholesterol carried by high-density lipoproteins (HDL-C). These alterations are connected to inflammation, which is a problem in severe liver disease. Herein, we show that reduced levels of HDL-C and apolipoprotein A-I (apoA-I, the main protein carried by HDL) are closely linked to the severity of liver failure, its complications and survival. Both HDL-C and apoA-I can be easily measured in clinical laboratories and are as good as currently used prognostic scores calculated from several laboratory values by complex formulas.
- Find related publications in this database (using NLM MeSH Indexing)
- Acute-On-Chronic Liver Failure - blood, diagnosis, epidemiology, metabolism
- Apolipoprotein A-I - blood, metabolism
- Biomarkers - administration & dosage
- Cholesterol, HDL - blood, metabolism
- Cross-Sectional Studies - administration & dosage
- Disease Progression - administration & dosage
- Europe - epidemiology
- Female - administration & dosage
- Humans - administration & dosage
- Lipoproteins, HDL2 - blood, metabolism
- Lipoproteins, HDL3 - blood, metabolism
- Liver Cirrhosis - blood, diagnosis, epidemiology
- Male - administration & dosage
- Middle Aged - administration & dosage
- Organ Dysfunction Scores - administration & dosage
- Predictive Value of Tests - administration & dosage
- Prognosis - administration & dosage
- Severity of Illness Index - administration & dosage
- Find related publications in this database (Keywords)
- HDL
- apoA-I
- MELD score
- ACLF
- Inflammation